Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02478931 · ClinicalTrials.gov registry record
Study of Personalized Cancer Therapy to Determine Response and Toxicity
A clinical trial of Cancer, sponsored by Shu Mei Kato.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 3
- Study locations
NCT02478931: Recruiting study of Cancer, sponsored by Shu Mei Kato.
NCT02478931 is a study of Cancer that is actively recruiting participants, run by Shu Mei Kato. The registered enrollment target is 10,000 participants, above the 3,475-participant average among 615 other Cancer trials with a reported enrollment target (188% higher). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02478931, a study of Cancer, is actively recruiting participants, sponsored by Shu Mei Kato.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from medical records to help the researchers determine whether or not patients respond better when their physicians choose to treat them according to the genetic makeup of their tumor. Optional research tests may be performed on tissue, body cavity fluid, blood or urine provided, discarded biological samples taken during routine care that would normally be disposed of and not saved, or on blood samples collected for this study. These research tests will be used to create a "profile" of the collected specimens which will describe unique characteristics about the genes involved in a person's cancer. The tests will also help researchers look for biomarkers that may help predict how people respond to treatment.
Primary Outcome
Tumor molecular profiles will be correlated to treatment outcome, assessed by measures including the response rate, the rate of stable disease (SD)\>6months/partial response (PR)/complete response (CR), progression-free survival (PFS), PFS ratio (comparison of the PFS used after molecular profiling to PFS on prior treatment), time to treatment failure, and overall survival. Logistic regression models (univariable and multivariables) will be used when the outcome variable is dichotomous. Kaplan-m
Conditions Studied
Study Locations (3)
California
- UCSD Moores Cancer Center - La Jolla
- Eisenhower Medical Center, Lucy Curci Cancer Center - Rancho Mirage
- Rady Children's Hospital, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2013-09-05 |
| Est. Completion | 2026-09-05 |
What NCT02478931 shows while recruiting
NCT02478931 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,475-participant average among 615 other Cancer trials with a reported enrollment target (188% higher).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02478931 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02478931 about?
NCT02478931 is a clinical study titled "Study of Personalized Cancer Therapy to Determine Response and Toxicity". The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from medical records to help the researchers determine whet...
What is the current status of trial NCT02478931?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2013-09-05. Estimated completion is 2026-09-05.
What conditions does trial NCT02478931 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT02478931?
This trial is sponsored by Shu Mei Kato, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02478931 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02478931's enrollment target sits among peer trials
10,000 23rd of 615 higher than 584 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
- NCT01000883 · 10,000 participants
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI